Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins

Circulation Research

Volumn 100, Issue 10, 2007, Pages 1394-1395

  Paumelle, Réjane ^a,b,c   Staels, Bart ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CYCLOOXYGENASE 2; FATTY ACID BINDING PROTEIN; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE C; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; EDITORIAL; ENZYME ACTIVATION; HEART PROTECTION; HUMAN; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CHOLESTEROL, LDL; CYCLOOXYGENASE 2; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR ALPHA; PPAR GAMMA;

EID: 34249655208     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000269334.42814.d2     Document Type: Editorial

References (13)

1. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A. 1999;96:11041-11048.
2. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
3. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, Takuwa T, Brownlee M, Nishikawa T, Araki E. Statins activate PPARγ through ERK1/2 and p38 MAPK-dependent COX-2 production in macrophages. Circ Res. 2007;100:1442-1451.
4. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists. Am J Cardiol. 2007;99: 27B-40B.
5. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int J Obes Relat Metab Disord. 2003;27:Suppl 3: S41-S45.
6. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005;280:22212-22221.
7. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.
8. Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, Linard C, Staels B, Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-α-dependent. J Biol Chem. 2004;279: 45512-8.
9. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, Fruchart JC, Briggs M, Spiegelman BM, Auwerx J. Regulation of peroxisome proliferator- activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol. 19:5495-5503, 1999.
10. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98:361-369.
11. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor α. Mol Endocrinol. 2004;18:1906-1918.
12. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462-468.
13. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005;45:1649-1653.